The renaissance of platinum-based chemotherapy for metastatic breast cancer

Journal of Chemotherapy

Volumn 20, Issue 5, 2008, Pages 551-560

  Meriggi, F ^a   Di Biasi, B ^a   Zaniboni, Alberto ^a  

^a Fondazione Poliambulanza   (Italy)

Author keywords

Anthracylines; Carboplatin; Cisplatin; Metastatic breast cancer; Oxaliplatin; Platinum compounds; Taxanes; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LONIDAMINE; METHOTREXATE; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; FATIGUE; FEBRILE NEUTROPENIA; HAIR LOSS; HUMAN; INFECTION; LEUKOPENIA; LOADING DRUG DOSE; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVIEW; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 57049165000     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.5.551     Document Type: Review

References (131)

1. Quinn M, Babb P, Brock A, Kirby L, Jones J. Breast cancer trends in England and Wales 1950-1999. London: the Stationery Office, 2001; 40-45.
2. Martin M. "Platinum compounds in the treatment of advanced breast cancer". Clin. Breast Cancer 2001; 190-208.
3. Smith IE, Talbot DC. "Cisplatin and its analogues in the treatment of advanced breast cancer: a review" Br. J. Cancer 1992; 787-793.
4. Dixit M, Yang JL, Poirier MC et al. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst 1997;(89): 365-373.
5. Pegram MD, Lopez A, Konecny G, et al. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000 (suppl 11);(27): 21-25.
6. Reed E. Cisplatin and analogs. In: Chabner BA, Longo DL editors. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia: Lippincott Wiliams and Wilkins 2001: 447-465.
7. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;(17): 409-422.
8. Pascoe JM, Roberts JJ. Interactions between mammalian cell DNA and inorganic platinum compounds: II. Interstrand cross-linking of isolated and cellular DNA by platinum (IV) compounds. Biochem Pharmacol 1974;(23): 1345-1357.
9. Canetta R, Goodlow J, Smaldone L, et al. Pharmacologic characteristics of carboplatin: clinical experience. In: Bunn PA, Canetta R, Ozols RF et al., editors. Current Perspectives and future directions. Philadelphia: WB Saunders 1990: 19-38.
10. Raymond E, Faivre S, Woynarowsky JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;(25): 4-12.
11. Brienza S, Gastiaburu J, Cvitkovic E, et al. Clinical characteristics and reversibility of neurological signs after long-term oxaliplatin (L-OHP) therapy. Ann Oncol 1994 (suppl 5):128 (abstr 225).
12. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Martyn M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;(25): 299-303.
13. Kolaric K, Roth A. Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983;(11): 108-112.
14. Sledge Jr GW, Loehrer PJ, Sr BJ, Roth LH. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 1988;(6): 1811-1814.
15. Mechl Z, Sopkova B. CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer. Neoplasma 1984;(31): 431-435.
16. Bajorin D, Bosl GJ, Fein R. Phase I trial of escalating doses of cisplatin in hypertonic saline. J Clin Oncol 1987;(5): 1589-1593.
17. Foresterie AA, Hakes TB, Wittes JT, Wittes RE. Cisplatin in the treatment of metastatic breast carcinoma: a prospective randomized trial of two dosage schedules. Am J Clin Oncol 1982;(5): 243-247.
18. Martino S, Samal BA, Singhakowinta A, et al. A phase II study of cis-diamminochloroplatinum II for advanced breast cancer. Two dose schedules. J Cancer Res Clin Oncol 1984;(108): 354-356.
19. Ostrow S, Egorin M, Aisner J, Bachur N, Wiernik PH. High-dose cis-diamminochloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials 1980;(3): 23-27.
20. Ramnath N, Lo Russo P, Simon M, Martino S. Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer. Am J Clin Oncol 1997;(20): 368-372.
21. Yap HY, Salem P, Hortobagy GN, et al. Phase II study of cis-diamminochloroplatinum (II) in advanced breast cancer. Cancer Treat Rep 1978;(62): 405-408.
22. Crown J. Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist 2001;(6): 17-21.
23. Schabel Jr FM, Trader MW, Laster Jr WR, Corbett TH, Griswold Jr DP. cis-Dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979;(63): 1459-1473.
24. Durand RE, Goldie JH. Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 1987;(71): 673-679.
25. Remick SC, Chmura M, Bromberg C, Sporn J, Healey B, Hilstro J. Concurrent 72-h continuous infusion of etoposide and cisplatin in metastatic breast cancer. Am J Clin Oncol. 1996;125-131.
26. Cocconi G, Bisagni G, Bacchi M, Boni C, Bartolucci R, Ceci G. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1991;664-669.
27. Lluch A, Azagra P, Cervantes A, et al. Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma. Oncology 1994;352-355.
28. Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999;1599-1605.
29. Tinsley R, Fuks J, Korzun A. Cisplatin and etoposide for advanced breast cancer. Proc Am Soc Clin Oncol 1986;287.
30. Krook JE, Loprinzi CL, Schaid DJ, Kardinal CG, Mailliard JA, Pfeifle DM. Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer. A collaborative North Central Cancer Treatment Group/Mayo Clinic phase II study. Cancer 1990;418-421.
31. Fried G, Stein ME, Haim N. Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: a phase II study. Med Pediatr Oncol 2000;10-13.
32. Ceci G, Bisagni G, Cocconi G, Rodino C, Belsanti V, Bertusi M. Cisplatin and VP16 in metastatic breast carcinoma as a third-line chemotherapy: a randomized study comparing low versus high doses of cisplatin. Tumori 1995;241-244.
33. Icli F, Akbulut H, Uner A, Bulent Y, Altinbas M, Baltali E. Paclitaxel (T) vs cisplatin+VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: a phase III randomized study, Turkish Oncology Group. Ann Oncol 2002; 47.
34. Cox EB, Burton GV, Olsen GA, Vugrin D. Cisplatin and etoposide: an effective treatment for refractory breast carcinoma. Am J Clin Oncol 1989;53-56.
35. Icli F, Gunel N, Dincol D, Karaoguz H, Demirkazik A. Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer. J Surg Oncol 1992;251-253.
36. Bromberg C, Remick S, Harper G. Concurrent 72 h contiuous infusion of etoposide and cisplatin in metastatic breast cancer. Proc Am Soc Clin Oncol 1991; 49.
37. Levitt NC, Dobbs NA, Braybrooke J. A phase I/II study of cisplatin and pharmacokinetically guided infusional etoposide phosphate in anthracycline resistant breast cancer. Proc Am Soc Clin Oncol 1999; 112.
38. Cocconi G, Tonato M, Di Costanzo F, et al. Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C). Eur J Cancer Clin Oncol 1986;761-764.
39. Athanassiades P, Bacoyiannes H, Kontoyiannes D. Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy. Chemioterapia 1986;125-127.
40. Giaccone G, Donadio M, Ferrati P, Calciati A. Cisplatin and etoposide in chemotherapy-refractory advanced breast cancer. Tumori 1988;191-193.
41. Sparano JA, Neuberg D, Glick JH, et al. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1997;1880-1884.
42. McCaskill-Stevens W, Ansari R, Fisher W. Phase II study of biweekly cisplatin (C) and paclitaxel (P) in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1996; 120.
43. Gelmon KA, O'Reilly SE, Tolcher AW, Campbell C, Bryce C, Ragaz J. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996;1185-1191.
44. Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 1996;1993-1999.
45. Browne MJ, Kennedy T, Cummings F. Phase II study of sequential taxol and cisplatin for the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1995;136.
46. Ezzat A, Raja MA, Berry J, et al. A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer. Ann Oncol 1997; 663-667.
47. Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. Breast Cancer Res. Treat. 1998;13-26.
48. Gainford C, O'Leary M, El-Fiki T. Phase I trial of docetaxel (T) and cisplatin (P) as first-line chemotherapy for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000; 113a.
49. Crown J, Fumoleau P, Kerbrat P. Phase I trial of docetaxel (D) with cisplatin (P) as first-line chemotherapy of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1997; 233a.
50. Llombart-Cussac A, Spielmann M, Dohollou N. Cisplatin-taxotere phase I/ II trial in patients with anthracycline-resistant advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1997;551.
51. Pescia V, Bordenave HR, Foglia S. Taxotere (T) and cisplatin (P) in anthracycline-pretreated advanced breast cancer (ABC): preliminary results. Proc Am Soc Clin Oncol 2000;117a.
52. Antoine E, Meric JB, Coeffic D. Anthracycline-primary resistant breast cancer: confirmatory results of the high level of activity of the docetaxel-cisplatin regimen. Proc Am Soc Clin Oncol 1999;129a.
53. Bernard A, Antoine EC, Gozy M. Docetaxel and cisplatin in anthracycline-pretreated advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1998;128a.
54. Vogel CL, Nabholtz JM. Monotherapy of metastatic breast cancer: a review of newer agents. Oncologist 1999;17-33.
55. Spielmann M, Zelek L, Nabholtz JM, Tonkin K, Aapro MS. Editors, Breast Cancer Management. Application of Evidence to Patient Care, Martin-Dunitz, London, 2000.
56. Hochster H, Wasserheit C, Siddiqui N. Vinorelbine/cisplatin therapy of locally advanced and metastatic breast cancer: an active regimen. Proc Am Soc Clin Oncol 1997: 173a.
57. Mustacchi G, Muggia M, Milani S, Ceccherini R, Leita ML, Dellach C. A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer. Ann Oncol 2002;(13): 1730-1736.
58. Shamseddine AI, Taher A, Dabaja B, Dandashi A, Salem Z, El Saghir NS. Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer. Am J Clin Oncol 1999;298-302.
59. Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer 1998;134-140.
60. Vassilomanolakis M, Koumakis G, Barbounis V, Demiri M, Pateras H, Efremidis AP. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. Ann Oncol 2000;1155-1160.
61. Gunel N, Akcali Z, Yamac D, Onuk E, Yilmaz E, Bayram O. Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer. Tumori 2000;283-285.
62. Szatkowska L, Mazurkiewicz M, Brzozowska A. Cisplatin and vinorelbine therapy of previously treated advanced breast cancer (preliminary studies). Pol Merkuriusz Lek 2001; 148-149.
63. Nolè F, Munzone E, Mandala M, et al. Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study. Ann Oncol 2001;(12): 95-100.
64. Jones AL, Smith IE, O'Brien ME, Talbot D, Walsh G, Ramage F. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol 1994;1259-1265.
65. Eisen T, Smith IE, Johnston S, Ellis PA, Prendiville J, Seymour MT. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol 1998;1350-1357.
66. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;72-79.
67. Van Moorsel CJ, Veerman G, Bergman AM, et al. Combination chemotherapy studies with gemcitabine. Semin Oncol 1997; S7-23.
68. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000; 2245-2249.
69. Galvez CA, Galmarini F, Curie M. Monthly cisplatin (C) and gemcitabine (G) as second line chemotherapy for patients with advanced breast cancer. Breast Cancer Res Treat 2000;81.
70. Heinemann V. Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clin Breast Cancer 2002;24-29.
71. Nagourney RA. Gemcitabine plus cisplatin in breast cancer. Oncology (Huntingt.) 2001;28-33.
72. Burch PA, Mailliard JA, Hillman DW. Phase II study of gemcitabine and cisplatin in patients with metastatic breast cancer (MBC) and failure on prior chemotherapy: a North Central Cancer Treatment Group trial. Breast Cancer Res Treat 2000;81.
73. Kolaric K, Vukas D. Carboplatin activity in untreated metastatic breast cancer patients - results of a phase II study. Cancer Chemother Pharmacol 1991;(27): 409-412.
74. Carmo-Pereira J, Dittrich C, Keizer J, et al. Phase II trial of carboplatin in carcinoma of the breast. Ann Oncol 1990;(1): 3-33 (abstract).
75. Martin M, Diaz-Rubio E, Casado A, et al. Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol 1992;(10): 433-437.
76. O'Brien ME, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 1993;(11):2112-2117.
77. Martin M, Diaz-Rubio E, Casado A, et al. Phase II study of carboplatin in advanced breast cancer: preliminary results. Semin Oncol 1991;(18) (suppl 2): 23-27.
78. Jodrell DI, Egorin MJ, Canetta RM, et al. Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992;(10):520-528.
79. Deltetto F, Durando A, Camanni M, et al. Carboplatin plus etoposide regimen in advanced breast cancer. A phase II study. Eur J Gynaecol Oncol 1997;185-187.
80. Van der Gaast A, Bontenbal M, Planting AS, Kok TC, Splinter TA. Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancer. Ann Oncol 1994;858-860.
81. Crown J, Hakes T, Reichman B, Lebwohl D, Gilewski T, Surbone A. Phase II trial of carboplatin and etoposide in metastatic breast cancer. Cancer 1993;1254-1257.
82. Fountzilas G, Skarlos D, Theoharis D, Giannakakis T, Stathopoulos G. Carboplatin and oral etoposide in the treatment of patients with advanced breast cancer refractory to anthracyclines. Tumori 1993;389-392.
83. Aguiar LF, Hegg R, Graziane SR. Phase II study of carboplatin and VP-16 (etoposide) association in first line treatment of advanced breast cancer. Proc Am Soc Clin Oncol 1993;83.
84. Hugli A, Sappino AP, Anchisi S, et al. Infusional ECarboF in patients with advanced breast cancer: a very active and well-tolerated out-patient regimen" Ann Oncol 2000;1557-1561.
85. Bonnefoi H, Smith IE, O'Brien ME, Seymour MT, Powles TJ, Allum WH. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisptatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. Br J Cancer 1996;391-396.
86. Closon MT, Verbeke L, Kains JP, Tijtgat J, Schallier D. Combination chemotherapy with carboplatin, cyclophosphamide and fluorouracil in advanced breast cancer" Anticancer Res 1995;591-595.
87. Brambilla C, Ferrari L, Passoni P, Bonadonna G. Carboplatin in combination as first-line therapy in advanced breast cancer. Cancer Treat Rev 1993;3-9.
88. Crown JP. The platinum agents: a role in breast cancer treatment? Sem Oncol 2001;(28 suppl 3):28-37.
89. Perez EA, Hillman DW, Stella PJ, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000;(88): 124-131.
90. Fountzilas G, Athanassiades A, Papadimitriou V, et al. Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer. Oncology (Huntington) 1998;(12 suppl 1): 45-48.
91. Loesch D, Robert N, Asmar L, et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002;(20): 3857-3864.
92. Fountzilas G et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by HECOG. Ann Oncol 2004;(15): 1517-1526.
93. Brufsky A, Matin K, Cleary D, et al. A phase II study of carboplatin and docetaxel as first line chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 2002;21:52b.
94. Fitch RA, Suman VJ, Mailliard JA et al. N9932: phase II cooperative group trial of docetaxel and carboplatin (CBDCA) as first-line chemotherapy for metastatic breast cancer (MBA). Proc Am Soc Clin Oncol 2003;22:23.
95. Perez EA. Carboplatin in combination therapy for metastatic breast cancer. Oncologist 2004;(9): 518-527.
96. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;(344): 783-792.
97. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer. J Nat Cancer Inst 2004;(96): 759-769.
98. Burris H, Yardley D, Jones S, et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004;(229): 1621-1629.
99. Robert N, Leyland-Jones B, Asmar I, et al. Randomized Phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;(24): 2786-2792.
100. Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005;(6): 425-32.
101. Pegram M, Forbes J, Pienkowski T, et al. On behalf of the BCIRG007 investigators. BCIRG007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2007;(25): 34s, abstract LBA1008.
102. Mathe G, Kidani Y, Triana K, Brienza S, Ribaud P, Goldschmidt E. A phase I trial of trans-1-diaminocyclohexane oxalatoplatinum (I-OHP). Biomed Pharmacother 1986; 372-376.
103. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990;1046-1050.
104. Garufi C, Nistico C, Brienza S, Vaccaro A, D'Ottavio A, Zappala AR. Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol 2001; 179-182.
105. Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol 2002;2551-2558.
106. Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. Ann Oncol 2003;(14): 537-542.
107. Thuss-Patience PC, Von Minckwitz G, Kretzschamar A, Loibl S, Schaller G, Dörken B. Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study. Anticancer Drugs 2003;(14): 549-53.
108. Caruba T, Cottu PH, Madelaine-Chambrin I, Espié M, Misset JL, Gross-Goupil M. Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients. Breast J 2007;(13): 165-71.
109. Kakolyris S, Kalbakis K, Potamianou A, et al. Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study. Oncology 2006;(70): 273-279.
110. Airoldi M, Cattel L, Passera R, Pedani F, Delprino L, Micari C. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. Am J Clin Oncol 2006;(29): 490-494.
111. Penault-Llorca FM, Nayl B, Mouret-Reynier M, et al. Gemcitabine oxaliplatin (GEMOX) is an active combination in heavily pretreated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2007;(25): 52s, abstract 1082.
112. Delozier T, Guastalla JP, Yovine A, et al. A phase II study of an oxaliplatin/vinorelbine/5fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. Anticancer Drugs 2006;(17): 1067-1073.
113. Petit T, Benider A, Yovine A, et al. Phase II study of an oxaliplatin/ vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer. Antican-cancer Drugs 2006;(17): 337-43.
114. Baur M, Drescher A, Gneist M, Dittrich C, Jaehde U. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction. Cancer Chemother Pharmacol 2007 Mar 30 [Epub ahead of print].
115. Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 2004;(4): 53-81.
116. Crown J, Pegram M. Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy. Breast Cancer Res Treat 2003;(79 suppl 1): S11-S18.
117. Belani CP. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, genitourinary tumors and myeloma. Semin Oncol 2004;(31 suppl. 14): 25-33.
118. Carrick S, Ghersi D, Wilcken N, Simes J. Platinum containing regimens for metastatic breast cancer (Review). The Cochrane Library 2007, Issue 2.
119. Chia JW, Ang P, See H, et al. Triple-negative metastatic/recurrent breast cancer: treatment with paclitaxel/carboplatin combination chemotherapy. Proc Am Soc Clin Oncol 2007;25:53s, abstract 1086.
120. Li HC, Russell CA. Gemcitabine and platinum-based chemotherapy in metastatic breast cancer. Oncology 2004;18 (suppl 12).
121. Laessig D, Vehling-Kaiser U, Stemmler HJ, et al. Evaluation of gemcitabine plus carboplatin in pretreated, metastatic breast cancer patients: Final analysis of a phase II trial. Proc Am Soc Clin Oncol 2007;25:50s, abstract 1074.
122. Ruiz M, Salvador J, Bayo J, et al. Phase-II study of weekly schedule of trastuzumab, paclitaxel and carboplatin followed by a week off every 28 days for HER 2+ metastatic breast cancer. Cancer Chemother Pharmacol 2008; [Epub ahead of print]
123. Moura GL, Pasquini R, Frare A, Vianna K, Albini L, Padilha S. Gemcitabine and cisplatin in metastatic breast cancer. Proc Am Soc Clin Oncol 2007;25:53s, abstract 1084.
124. Oksuzoglu B, Abali H, Ozdemir N, Budakoglu B, Hayran M, Zengin N. Capecitabine/cisplatin doublet in anthracycline and taxane pre-treated patients with metastatic breast carcinoma. Proc Am Soc Clin Oncol 2007;25:55s, abstract 1093.
125. Xu B, Jiang Z, Kim S, et al. Randomized phase II study of biweekly gemcitabine (gem)-pactitaxel (pac), gem-carboplatin (carb) and gem-cisplatin (cis) as first-line treatments in metastatic breast cancer (MBC) after anthracycline failure. Proc Am Soc Clin Oncol 2007;25:56s, abstract 1099.
126. Peria FM, Zola FE, Tizzi DG, et al. Combination chemotherapy with gencitabine and cisplatin in anthracycline and taxane pretreated metastatic breast cancer. Proc Am Soc Clin Oncol 2007;25:59s, abstract 1108.
127. Leong C, Vidnovic N, DeYoung M et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007;117:1370-80.
128. Kong C, Zhu Y, Sun C, et al. Inhibition of tumor angiogenesis during cisplatin chemotherapy for bladder cancer improves treatment outcome. Urology 2005;65:395-9.
129. Battacharyya A, Ear US, Koller BH et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-903.
130. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008; 14: 1291-5.
131. Yde CW, Gyrd-Hansen M, Lykkesfeldt AE et al. Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther 2007;6:1869-76